Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).

Shao, Guoliang; Bai, Yuxian; Chen, Xiaohong; Gu, Shanzhi; Gu, Kangsheng; Yuan, Xianglin; Widau, Ryan C.; Zhang, Wanli; Zhang, Qiang; Qin, Shukui

doi:10.1200/jco.2022.40.16_suppl.e16081

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).

NobleIDNI5P58W17R92S00

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/002CADE6.svg?ark=w1%2F20260521%2F002CADE6&value=id)](https://nobleid.org/work/w1/20260521/002CADE6)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).

NobleIDNI5P58W17R92S00

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/002CADE6.svg?ark=w1%2F20260521%2F002CADE6&value=id)](https://nobleid.org/work/w1/20260521/002CADE6)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work